Project: Developing a personalized biological therapy for the treatment of pancreatic and ovarian cancer.
| Acronym | ELEVATE (Reference Number: 114014) |
| Duration | 01/09/2020 - 01/09/2023 |
| Project Topic | ELEVATE will deliver EL-mab, a first-in-class monoclonal antibody (mAb) drug for the personalized treatment of pancreatic ductal adenocarcinoma (PDAC) and ovarian cancers (OvaC). EL-mab is a bispecific mAb, targeting L1CAM on cancer cells and CD3 on T-cells, and will be accompanied by complementary solid and liquid biopsy diagnostics for patient selection and treatment monitoring. By the end of ELEVATE, EL-mab and companion diagnostics will be ready for validation in Phase 2 clinical trials. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 12 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Institute of Experimental Cancer Research (Institut für Experimentelle Tumorforschung) | Partner | Germany |
| 2 | Elthera AG | Coordinator | Switzerland |
| 3 | iCellate Medical AB | Partner | Sweden |
| 4 | Targos Molecular Pathology GmbH | Partner | Germany |